UniSa - IRIS Institutional Research Information System

MASARONE, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.855
NA - Nord America 5.614
EU - Europa 2.238
SA - Sud America 789
AF - Africa 127
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 17.634
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 5.760
US - Stati Uniti d'America 5.463
SG - Singapore 1.320
IT - Italia 924
CN - Cina 648
BR - Brasile 605
VN - Vietnam 475
RU - Federazione Russa 281
UA - Ucraina 191
DE - Germania 168
FR - Francia 154
TR - Turchia 130
IE - Irlanda 126
KR - Corea 111
BD - Bangladesh 103
GB - Regno Unito 79
AR - Argentina 77
CA - Canada 73
SE - Svezia 73
FI - Finlandia 65
IN - India 63
MX - Messico 44
ZA - Sudafrica 43
JP - Giappone 37
IQ - Iraq 36
EC - Ecuador 33
ID - Indonesia 33
NL - Olanda 32
DK - Danimarca 27
PL - Polonia 24
VE - Venezuela 22
CO - Colombia 21
PK - Pakistan 21
ES - Italia 19
AT - Austria 17
UZ - Uzbekistan 15
MA - Marocco 14
SA - Arabia Saudita 13
CZ - Repubblica Ceca 12
PY - Paraguay 12
EG - Egitto 11
AE - Emirati Arabi Uniti 10
MY - Malesia 9
PS - Palestinian Territory 9
HN - Honduras 8
KE - Kenya 8
PH - Filippine 8
AL - Albania 7
GR - Grecia 7
KZ - Kazakistan 7
LT - Lituania 7
TN - Tunisia 7
AZ - Azerbaigian 6
DZ - Algeria 6
JM - Giamaica 6
PE - Perù 6
SN - Senegal 6
CR - Costa Rica 5
EU - Europa 5
RO - Romania 5
AU - Australia 4
CG - Congo 4
CL - Cile 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
IL - Israele 4
JO - Giordania 4
NO - Norvegia 4
OM - Oman 4
UG - Uganda 4
AO - Angola 3
BH - Bahrain 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CI - Costa d'Avorio 3
ET - Etiopia 3
LY - Libia 3
NP - Nepal 3
PT - Portogallo 3
QA - Qatar 3
UY - Uruguay 3
CH - Svizzera 2
GE - Georgia 2
GY - Guiana 2
IR - Iran 2
LB - Libano 2
LV - Lettonia 2
MW - Malawi 2
RS - Serbia 2
SC - Seychelles 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BJ - Benin 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
Totale 17.611
Salva come PNG Salva come JPEG
Città #
Hong Kong 5.750
Ann Arbor 778
San Jose 652
Singapore 640
Chandler 360
Ashburn 346
Princeton 344
Woodbridge 334
Milan 331
Jacksonville 263
Dallas 247
Houston 179
Beijing 167
Council Bluffs 141
The Dalles 140
Dublin 123
Ho Chi Minh City 123
Lauterbourg 108
Dong Ket 106
Izmir 106
Wilmington 102
Hanoi 87
Los Angeles 87
Rome 83
Moscow 74
Nanjing 73
New York 66
Andover 63
São Paulo 58
Munich 56
Naples 52
Santa Clara 49
Boardman 45
Pellezzano 44
Tokyo 35
Memphis 32
Salerno 28
Fairfield 27
Johannesburg 26
Redwood City 26
Changsha 24
Norwalk 24
Brooklyn 23
Hebei 23
Montreal 23
Figino 22
Frankfurt am Main 22
Shenyang 22
Turin 22
Turku 22
Columbus 21
Haiphong 21
Rio de Janeiro 21
Warsaw 20
Washington 20
Orem 19
Amsterdam 18
Chennai 18
Denver 18
Mexico City 18
Stockholm 18
Belo Horizonte 17
Da Nang 17
Jinan 17
Nanchang 17
Chicago 16
Dearborn 16
Dhaka 16
London 16
Atlanta 15
Phoenix 15
Tashkent 15
Jiaxing 14
Nuremberg 14
Seattle 14
Baghdad 12
Brasília 12
Curitiba 12
Guayaquil 12
Helsinki 12
Tianjin 12
Copenhagen 11
Guangzhou 11
Manchester 11
Caracas 10
Fisciano 10
Jinju 10
Nürnberg 10
Poplar 10
San Diego 10
Toronto 10
Boston 9
City of London 9
Erbil 9
Maletto 9
Ninh Bình 9
Ottawa 9
Pontecagnano 9
Ankara 8
Biên Hòa 8
Totale 13.263
Salva come PNG Salva come JPEG
Nome #
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 768
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 765
Non Alcoholic Fatty Liver: Epidemiology and Natural History 628
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 609
Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study 498
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 441
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 397
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 380
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 347
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 321
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition 317
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 312
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 303
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 280
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 264
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 209
VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS 208
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 192
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 192
The diagnostic conundrum in non-alcoholic fatty liver disease 189
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 183
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 158
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 158
Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study 157
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 154
Coeliac disease and C virus-related chronic hepatitis: a non association 153
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 153
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 151
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 147
Alcoholic Liver Disease and Hepatitis C Chronic Infection 144
Epidemiology and Natural History of Alcoholic Liver Disease 143
Adiponectin in hepatology 143
Pharmacotherapy of alcoholic liver disease in clinical practice 142
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 133
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 132
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease 132
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 132
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 132
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 129
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 126
Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy 126
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 125
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 124
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus 123
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 122
Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea 122
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 121
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 119
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 119
Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate-a pilot study 116
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy 114
Viral hepatitis: Milestones, unresolved issues, and future goals 113
Lung ultrasound for diagnosis of pneumonia in emergency department 111
HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? 111
Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno 111
Efficacy and Safety of a Polysaccharide-Based Natural Substance Complex in the Treatment of Obesity and Other Metabolic Syndrome Components: A Systematic Review 109
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 109
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells 109
Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver 109
Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: A pilot study 107
Metabolic associated steatotic liver disease in renal transplant recipients: a retrospective cohort study 105
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 105
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy 104
Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease 103
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 103
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 103
HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era 103
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. 102
FN 44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION 102
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 101
Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. 100
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 100
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 99
Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic 96
Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis 96
Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study 96
Real‐Life Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Infected Patients with Chronic Kidney Disease 96
Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. 95
Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. 93
Hepatitis C Virus Infection and Non-Hepatocellular Malignancies in the DAA Era: A Systematic Review and Meta-Analysis 93
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System 92
Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study 90
HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 89
NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome 89
P. 253 Rapid virological response in genotype 1b patients treated with peginterferon plus ribavirin: evidence for a significant sustained virological response (SVR) after 24 weeks of therapy in peg-interferon-alpha-2a treated patients 88
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 88
Gut-Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers 87
HCV point-of-care screening program and treatment options for people who use drugs in a metropolitan area of Southern Italy 87
Corrigendum to “Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)” [Dig Liver Dis 54 (2022) 170–182, (S1590865821002140), (10.1016/j.dld.2021.04.029)] 84
Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study 83
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. 83
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 83
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 82
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 81
Artificial Intelligence and liver: Opportunities and barriers 81
A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 80
Solving the gap between HCV detection and treatment in prison. HCV-RNA testing and treatment in a cohort of new arriving convicts in Southern Italy 79
Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle? 77
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention 73
Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience 68
Totale 16.501
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.297
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.297
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022609 6 6 9 7 10 10 22 31 83 82 80 263
2022/2023918 102 72 54 110 99 189 3 67 135 5 60 22
2023/2024515 35 49 36 24 39 100 26 31 9 19 35 112
2024/20251.585 32 29 23 53 106 165 272 150 284 106 189 176
2025/202611.207 695 2.891 2.923 522 776 366 927 219 392 606 237 653
2026/202785 85 0 0 0 0 0 0 0 0 0 0 0
Totale 17.906